Release date: 24 August 2001
Promoter – Financial Intermediary
A company providing infrastructure in an industrial parkLocation
Description
Construction of a multi-purpose laboratory and an adjacent office building, including laboratory support functions, to be used by companies in the fields of pharmaceutical research and biotechnology.
Objectives
The project will help to increase the competitiveness and added value of a European industry and its industrial clients. The final user of the facilities is a global player in pharmaceutical research and drug development. Given the final user’s competences in R&D and role in diffusion of innovative processes and technologies, financing the underlying R&D-efforts corresponds to the Bank’s objectives set forth in the Innovation 2000 Initiative.
Comments
Pharmaceuticals and biotechnology
Sector(s)
Proposed EIB finance (Approximate amount)
EUR 28 million
Total cost (Approximate amount)
Approx. EUR 94 million
Environmental aspects
The project does not require an EIA under EC Directive 97/11.All the laboratory facilities will be equipped with advanced technology analysis and experimentation systems and will operate in strict compliance with national standards for health, safety and environment.
Procurement
The procurement procedures for civil works and equipment consisted of national and international enquiries amongst a group of pre-qualified suppliers.
Status
Signed - 14/02/2003
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).